BSE filing, NSE: WELCURE. Summary written from the filing by ALFA Finder's alert engine.
Welcure Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹0.19
- Market cap
- ₹23.48 Cr
- Revenue (annual)
- ₹365.5 Cr
- Net profit (annual)
- ₹-5.49 Cr
- P/E (TTM)
- -1.4×Sector 46.1×
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Welcure Drugs & Pharmaceuticals Ltd
All →Welcure Drugs & Pharmaceuticals Board Meeting Outcome
Welcure Drugs & Pharmaceuticals approved the closure of its Ahmedabad corporate office. Operations will continue uninterrupted with records transferred to the registered office.
Welcure Drugs & Pharmaceuticals Other Announcement
Welcure Drugs submitted its Annual Secretarial Compliance Report for FY2026 under Regulation 24A. The report confirms overall compliance while noting historical fines paid for earlier procedural delays.
Welcure Drugs & Pharmaceuticals Q4 FY26 Results: Net Loss of ₹49.9 Cr
Welcure Drugs & Pharmaceuticals Ltd reported a net loss of ₹49.9 Cr for Q4 FY26.
- Key figure
- Net loss ₹49.9 Cr
Welcure Drugs & Pharmaceuticals Financial Results
Welcure Drugs and Pharmaceuticals reported annual total income of ₹367.00 Crore for FY26. The Board approved audited results, showing a net annual loss of ₹5.49 Crore.
- Value
- ₹367.0 Cr
Welcure Drugs & Pharmaceuticals Board Meeting Date
Welcure Drugs scheduled a board meeting for May 29, 2026. Directors will consider and approve audited financial results for the 2026 fiscal year.
Welcure Drugs & Pharmaceuticals Debt & Borrowing
Welcure Drugs & Pharmaceuticals Ltd confirmed it does not meet SEBI's 'Large Corporate' criteria for the financial year ended March 31, 2026. Consequently, the company is exempt from mandatory incremental borrowing through debt securities. Its outstanding borrowings as of the reporting date were nil.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.